focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Regulatory Approvals for Collagen Solutions Client

10 Mar 2015 07:03

RNS Number : 9717G
Collagen Solutions PLC
10 March 2015
 

10 March 2015

 

Collagen Solutions Plc

(the "Company" or the "Group")

 

FDA 510(K) Clearance for NovaBone products

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, is pleased to announce that its customer NovaBone Products LLC (NovaBone) has received the following 510(K) clearances from the US Food and Drug Administration (FDA). These products have been developed by NovaBone using medical grade collagen supplied by the Collagen Solutions Group. This supply is made by both Collagen Solutions and by its wholly owned subsidiary, Southern Lights Biomaterials.

 

 

Name

Product Type

FDA clearance

NovaBone Bioactive Strip

Bone graft

Orthopaedics Division

NovaBone MacroForm Bioactive

Bone graft

Orthopaedics Division

NovaTape/ NovaPlug

Wound Dressing

Dental Division

 

 

Collagen Solutions provides the highest quality, medical grade biomaterials to support medical devices and other products for regenerative medicine across an increasingly wide range of applications and clinical indications. Collagen Solutions and Southern Lights have been providing specific medical grade collagen materials to NovaBone for a number of years and is pleased to see that these collagen-based products have received FDA 510(K) clearance in the US.

 

NovaBone is a privately held biomaterials company based in Florida, USA. The Company was established in 2002 with a focus on developing bone graft substitutes based on advancements in biomedical engineering that would meet the specialised needs of orthopaedic and dental surgeons. Their products have been available for over 10 years and been used in over a million clinical applications with unparalleled success validating the safety and efficacy of the NovaBone technology.

Dr Stewart White, Chief Executive Officer of Collagen Solutions plc said: "These three FDA clearances reinforce our strategy to release the embedded value we have created in manufacturing medical grade collagen products for our customers. Once we are identified as the source of raw material and that has been included as part of the regulatory submission process, it is highly likely that we will be supplying collagen for those products for their entire life cycle. The importance of our part in our customers' future is emphasised by the recent acquisition of Southern Lights, whose separate supply to NovaBone will continue."

 

"These three products are entering the high value added area of collagen based bone grafts and wound care products which is a rapidly growing market for novel products. That is, the bone graft market in the US is estimated to be worth US$3.3 Billion, whilst the wound dressing sector is worth around US$3 Billion."

 

The US regulatory clearances achieved by NovaBone further endorse the long and strong relationship we have with our customers. Through robust partnerships we offer technical support and reliable supply to our customers who are then able to provide the necessary collagen safety information to regulatory agencies to support market clearance for their finished devices. This is a significant success for the NovaBone team."

 

 

 

 

 

 

Enquiries:

 

Collagen Solutions Plc

 

David Evans, Chairman 

Tel: 07740 084 452

Stewart White, CEO

Tel: 0141 558 2008

 

 

Zeus Capital (Nominated Adviser and Broker)

 

Ross Andrews / John Depasquale

Tel: 020 7533 7727

Alex Davies

 

Panmure Gordon & Co (Joint Broker)

 

Robert Naylor (Corporate Finance)

Maisie Atkinson (Corporate Broking)

Tel: 020 7886 2714Tel: 020 7886 2905

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Mike Wort

Mob: 07900 608 002

Anna Dunphy

Mob: 07876 741 001

 

 

Further information:

 

NovaBone MacroForm and Bioactive Strip devices are osteoconductive bioactive bone void fillers used for orthopaedic applications. The devices are a mixture of bioactive calcium-phospho-silicate granules and a collagen binder. The bioactive glass particulate is composed solely of elements that exist in normal bone (Ca, P, Na, Si, O). The collagen component facilitates hydration with bone marrow aspirate and handling for application to the surgical site. During absorption of the collagen binder, the particulate material remaining undergoes a time-dependent kinetic modification of the surface to stimulate osteoblast activity and guide the formation of bone across the graft site. Specifically, a series of surface reactions on the particles results in the formation of a calcium phosphate layer that is substantially equivalent in composition and structure to the hydroxyapatite found in bone mineral. This apatite layer provides scaffolding onto which the patient's new bone will grow, allowing complete repair of the defect. During healing, the graft particulate is absorbed and remodeled into new bone.

 

NovaTape & NovaPlug Dental Collagen Wound Dressings are soft, white to off-white, resorbable collagen dressings produced from cross-linked purified collagen derived from bovine hide. The dressings are intended for the management of oral wounds and sores. The thickness and pore structure of the dressing allow it to absorb fluids and blood at the defect site, thereby maintaining a moist environment. The dressings resorb within approximately 14 days of implantation.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADXGDXRGGBGUC
Date   Source Headline
30th Aug 201711:21 amRNSResult of AGM
30th Aug 20177:00 amRNSAGM Statement
26th Jul 20177:00 amRNSPosting of Annual Report & notice of AGM
25th Jul 201711:36 amRNSDirector/PDMR Shareholding
25th Jul 20177:15 amRNSHardman Research: Transition to sustainable growth
13th Jul 201711:39 amRNSDirector/PDMR Shareholding
11th Jul 20177:00 amRNSFinal Results
7th Jul 20177:00 amRNSFirst patient enrolment in ChondroMimetic® study
19th Jun 20177:00 amRNSNotice of Results
13th Jun 20177:00 amRNSProvisional patent submitted
11th May 20177:15 amRNSHardman Research: Trading:earnings above forecasts
25th Apr 20177:00 amRNSTrading Update
24th Apr 20177:00 amRNSConsolidation of US R&D activities & Board change
10th Apr 20177:00 amRNSCollagen Based Spray Adhesive Poster Presented
3rd Apr 201711:22 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSAgreement signed with Smart Matrix Limited
31st Mar 20174:52 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSPericardium Divisional Patent in Australia
27th Mar 201712:39 pmRNSDirector/PDMR Shareholding
24th Mar 20179:26 amRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSAttending UK Investor Show
20th Mar 20178:56 amRNSIntroduces new online sales initiative in the US
15th Mar 20179:58 amRNSHolding(s) in Company
14th Mar 20173:28 pmRNSHolding(s) in Company
13th Mar 201711:52 amRNSHardman Research: Engineering cartilage repairs
13th Mar 20179:57 amRNSHolding(s) in Company
13th Mar 20177:05 amRNSHardman Research: Engineering cartilage repairs
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSAttending AAOS and ORS meetings in San Diego
8th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20174:08 pmRNSHolding(s) in Company
7th Mar 20171:01 pmRNSDirector/PDMR Shareholding
7th Mar 201711:19 amRNSHolding(s) in Company
7th Mar 20179:56 amRNSHolding(s) in Company
6th Mar 20172:24 pmRNSResult of General Meeting
20th Feb 20177:00 amRNSInvestor presentation
15th Feb 201711:29 amRNSGrant of Options
14th Feb 201711:24 amRNSHardman Research: Funding accelerated growth
14th Feb 20177:00 amRNSPlacing Open Offer and Debt Financing
7th Feb 20177:00 amRNSAttends MD&M West Conference in Anaheim
19th Jan 20177:00 amRNSNew Scientific Advisory Board appointments
13th Jan 20177:00 amRNSThird Medical Research Scotland Ph.D. Studentship
21st Dec 201612:06 pmRNSHardman Research: Foundations for strategic growth
19th Dec 20167:00 amRNSHalf-year Report
14th Dec 20167:00 amRNSPoster Presentation at TERMIS-AM
2nd Dec 20167:00 amRNSNotice of Results
13th Oct 20167:00 amRNSTrading Statement
3rd Oct 20167:00 amRNSChange of Adviser
15th Sep 20167:00 amRNSParticipation in major Horizon 2020 project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.